Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With A/H1N1, A Spectre Is Haunting China: The Spectre Of SARS

This article was originally published in PharmAsia News

Executive Summary

BEIJING - As China's government mulls whether to galvanize a dozen vaccine producers across the country to turn out up to 300 million doses of an A/H1N1 defense and continues with the rapid-fire quarantine of anyone suspected of having contact with swine flu victims, health authorities are meeting with World Health Organization representatives to coordinate closely Beijing's response to the pandemic

You may also be interested in...



China’s Healthcare Reforms A Great Start But Institutional Weakness Could Hamper Progress – The Lancet

China’s biggest weakness is institutional, which makes it difficult for its large and growing healthcare system to be effective, say report authors.

Asia Spotlight: China’s New SFDA Chief Has A Public Health Background, And International Ties

Vice Minister of Health Yin Li assumes post as director of China’s State FDA, taking the reigns from Shao Mingli, who led the agency since 2005.

Meet Yin Li: China’s New SFDA Chief Has A Public Health Background, And International Ties

Vice Minister of Health Yin Li assumes post as director of China’s State FDA, taking reigns from Shao Mingli, who led the agency since 2005.

Related Content

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel